Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
The malignant phenotype is largely the consequence of dysregulated gene expression. Transformed cells depend upon not just a global increase in protein synthesis but an altered translational landscape in which pro-oncogenic mRNAs are translationally up-regulated. Such mRNAs have been shown to possess longer and more structured 5′-UTRs requiring high levels of eukaryotic initiation factor 4A (eIF4A) helicase activity for efficient translation. As such there is a developing focus on targeting eIF4A as a cancer therapy. In order for such treatments to be successful, we must develop a detailed understanding of the mechanisms which make specific mRNAs more dependent on eIF4A activity than others. It is also crucial to fully characterize the potentially distinct roles of eIF4A1 and eIF4A2, which until recently were thought to be functionally interchangeable. This review will highlight the recent advances made in this field that address these issues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The RNA helicase eIF4A unwinds the complex 5′ UTR structures of cap-dependent transcripts and is a critical component of the eIF4F translational complex (10, 17).”
From Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer (2023) · cites this paper as [17]
Citations
Cites
Ji, P., Diederichs, S., Wang, W., Böing, S., Metzger, R., Schneider, P. M., Tidow, N., Brandt, B., Buerger, H., Bulk, E., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206928 · Cited by 2,189
Asangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882
An RNA G-quadruplex in the 5′ UTR of the NRAS proto-oncogene modulates translation
Kumari, S., Bugaut, A., Huppert, J. L., & Balasubramanian, S. (2007) · Nature Chemical Biology · doi:10.1038/nchembio864 · Cited by 822
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
The Scanning Mechanism of Eukaryotic Translation Initiation
Hinnebusch, A. G. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035802 · Cited by 798
S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth
Dorrello, N. V., Peschiaroli, A., Guardavaccaro, D., Colburn, N. H., Sherman, N. E., & Pagano, M. (2006) · Science · doi:10.1126/science.1130276 · Cited by 731
5'-UTR RNA G-quadruplexes: translation regulation and targeting
Bugaut, A., & Balasubramanian, S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks068 · Cited by 642
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Pestova, T. V., & Kolupaeva, V. G. (2002) · Genes & Development · doi:10.1101/gad.1020902 · Cited by 566
Hsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 434
Cited by
Cancer the‘RBP’eutics–RNA-binding proteins as therapeutic targets for cancer
Mohibi, S., Chen, X., & Zhang, J. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.07.001 · Cited by 199
Aptamers: Uptake mechanisms and intracellular applications
Yoon, S., & Rossi, J. J. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.003 · Cited by 169
Tailor made: the art of therapeutic mRNA design
Metkar, M., Pepin, C. S., & Moore, M. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00827-x · Cited by 178
Wanted DEAD/H or Alive: Helicases Winding Up in Cancers
Cai, W., Chen, Z. X., Rane, G., Singh, S. S., Choo, Z., Wang, C., Yuan, Y., Tan, T. Z., Arfuso, F., Yap, C. T., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw278 · Cited by 119
Wilczynska, A., Gillen, S. L., Schmidt, T., Meijer, H. A., Jukes-Jones, R., Langlais, C., Kopra, K., Lu, W.-T., Godfrey, J. D., Hawley, B. R., et al. (2019) · Genome Biology · doi:10.1186/s13059-019-1857-2 · Cited by 62
Self-citation
Metadata
- Authors
- Raza, F., Waldron, J. A., & Quesne, J. L.
- Affiliations
- Medical Research Council (GB)
- Medical Research Council Toxicology Unit, Lancaster Road, Leicester, LE1 9HN, U.K.
- Corresponding author
- Raza, Farheen
- Venue
- Biochemical Society Transactions
- Publisher
- Portland Press Ltd.
- Published
- 2015-11-27
- Volume
- 43
- Issue
- 6
- Pages
- 1227-1233
- ISSN
- 0300-5127 (ISSN-L)
- 1470-8752
- OpenAlex
- W2179151406
- Cited by
- 61
- References
- 60
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 10 · 2022: 4 · 2021: 10 · 2020: 6 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 1
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Society Transactions (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- eIF4A, eIF4A1, EIF4A2, translation initiation
- MeSH terms
- Benzofurans, Epoxy Compounds, Humans, Neoplasms, Sterols, Thiazoles, Protein Biosynthesis, Triterpenes, Gene Expression Regulation, Neoplastic, Macrolides, Protein Isoforms, Eukaryotic Initiation Factor-4A, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence. https://app.cochat.ai/papers/10.1042/bst20150163
- The paper
- Raza, F., Waldron, J. A., & Quesne, J. L. (2015). Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence. Biochemical Society Transactions. https://doi.org/10.1042/bst20150163
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.